2023 Annual Meeting Daily: Sunday, April 23

DAYBUE ™ is now FDA approved to treat Rett syndrome 1

DAYBUE is the first and only FDA-approved treatment for Rett syndrome (RTT) in adult and pediatric patients 2 years and older.1,2 RTT is a complex neurodevelopmental disorder with symptoms that can impact the ability to function.3-5

1 pm to 1:20 pm in-booth presentation

1 pm to 1:20 pm

Emerging Neurologic Care Presentation Stage (in the Exhibit Hall)

1 pm to 1:20 pm in-booth presentation

Indication

Come see us at Booth #1384 to learn more about Rett syndrome and DAYBUE

DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.

Important Safety Information

• Warnings and Precautions

– Diarrhea: In a 12-week study and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy. Diarrhea severity was of mild or moderate severity in 96% of cases. In the 12-week study, antidiarrheal medication was used in 51% of patients treated with DAYBUE.

– Patients should stop taking laxatives before starting DAYBUE. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed. Interrupt, reduce dose, or discontinue DAYBUE if severe diarrhea occurs or if dehydration is suspected.

– Weight Loss: In the 12-week study, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE if significant weight loss occurs.

• Adverse Reactions: The common adverse reactions (≥5% for DAYBUE-treated patients and at least 2% greater than in placebo) reported in the 12-week study were diarrhea (82% vs 20%), vomiting (29% vs 12%), fever (9% vs 4%), seizure (9% vs 6%), anxiety (8% vs 1%), decreased appetite (8% vs 2%), fatigue (8% vs 2%), and nasopharyngitis (5% vs 1%).

• Drug Interactions: Effect of DAYBUE on other Drugs

– DAYBUE is a weak CYP3A4 inhibitor; therefore, plasma concentrations of CYP3A4 substrates may be increased if given concomitantly with DAYBUE. Closely monitor when DAYBUE is used in combination with orally administered CYP3A4 sensitive substrates for which a small change in substrate plasma concentration may lead to serious toxicities.

– Plasma concentrations of OATP1B1 and OATP1B3 substrates may be increased if given concomitantly with DAYBUE. Avoid the concomitant use of DAYBUE with OATP1B1 and OATP1B3 substrates for which a small change in substrate plasma concentration may lead to serious toxicities.

• Use in Specific Population: Renal Impairment

– DAYBUE is not recommended for patients with moderate or severe renal impairment. DAYBUE is available as an oral solution (200mg/mL).

Read the Brief Summary of full Prescribing Information on the following page.

References: 1. Acadia Pharmaceuticals Inc. DAYBUE [Package Insert]. San Diego, CA, 2023. 2. Acadia Pharmaceuticals announces U.S. FDA approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. [press release]. Acadia Pharmaceuticals Inc. March 10, 2023. 3. Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatr Open. 2020;4(1):e000717. 4. Neul JL, Kaufmann WE, Glaze DG, et al for the RettSearch Consortium. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944-950. 5. Anderson A, Wong K, Jacoby P, et al. Twenty years of surveillance in Rett syndrome: what does this tell us? Orphanet J Rare Dis. 2014;9:87. 6. International Rett Syndrome Foundation. IRSF expands center of excellence network. Accessed March 14, 2023. https://www.rettsyndrome.org

®

©2023 Acadia Pharmaceuticals Inc. Acadia is a registered trademark and DAYBUE is a trademark of Acadia Pharmaceuticals Inc. All rights reserved. DAY-0082 03/23

DAYBUE™ (trofinetide) oral solution

Rx Only

Brief Summary: This information is not comprehensive. Visit www.DAYBUEhcp.com to obtain the full Prescribing Information or call 1-844-422-2342

1 INDICATIONS AND USAGE

DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.

2 DOSAGE AND ADMINISTRATION

Administer DAYBUE orally twice daily, in the morning and evening, according to patient weight as shown in the table below. DAYBUE can be taken with or without food.

Recommended Dosage of DAYBUE in Patients

2 years of age and older

Patient Weight DAYBUE Dosage DAYBUE Volume

9 kg to <12 kg 5,000 mg twice daily 25 mL twice daily

≥12 kg to <20 kg 6,000 mg twice daily 30 mL twice daily

≥20 kg to <35 kg

8,000 mg twice daily 40 mL twice daily

≥35 kg to <50 kg 10,000 mg twice daily 50 mL twice daily

≥50 kg 12,000 mg twice daily 60 mL twice daily

Administration Information

Administer DAYBUE orally or via gastrostomy (G) tube; doses administered via gastrojejunal (GJ) tubes must be administered through the G-port. A calibrated measuring device, such as an oral syringe or oral dosing cup, should be obtained from the pharmacy to measure and deliver the prescribed dose accurately. A household measuring cup is not an adequate measuring device. Discard any unused DAYBUE oral solution after 14 days of first opening the bottle.

Missed Dose or Vomiting After Administration

If a dose of DAYBUE is missed, the next dose should be taken as scheduled. Doses should not be doubled. If vomiting occurs after DAYBUE administration, an additional dose should not be taken. Instead, continue with the next scheduled dose.

Dose Modification for Diarrhea or Weight Loss

Advise patients to stop laxatives before starting DAYBUE. Interrupt, reduce the dosage, or discontinue DAYBUE if severe diarrhea occurs, if dehydration is suspected, or if significant weight loss occurs.

5 WARNINGS AND PRECAUTIONS

Diarrhea

In a 12-week randomized, double-blind, placebocontrolled study (Study 1) and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy. Diarrhea severity was of mild or moderate severity in 96% of cases. In Study 1, antidiarrheal medication was used in 51% of patients treated with DAYBUE.

Advise patients to stop laxatives before starting DAYBUE. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed. Interrupt, reduce dose, or discontinue DAYBUE if severe diarrhea occurs or if dehydration is suspected.

Weight Loss

In Study 1, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE if significant weight loss occurs.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in labeling:

• Diarrhea [see Warnings and Precautions]

• Weight Loss [see Warnings and Precautions]

Clinical trial experience

In controlled and uncontrolled trials in patients with Rett syndrome, 260 patients ages 2 to 40 years were treated with DAYBUE, including 109 patients treated for more than 6 months, 69 patients treated for more than 1 year, and 4 patients treated for more than 2 years.

Adult and Pediatric Patients with Rett Syndrome 5 Years of Age and Older

The safety of DAYBUE was evaluated in a randomized, double-blind, placebo-controlled, 12-week study of patients with Rett syndrome (Study 1). In Study 1, 93 patients received DAYBUE, and 94 patients received placebo. All patients were female, 92% were White, and the mean age was 11 years (range 5 to 20 years).

Adverse Reactions Leading to Discontinuation of Treatment

Eighteen patients (19%) receiving DAYBUE had adverse reactions that led to withdrawal from the study. The most common adverse reaction leading to discontinuation of treatment with DAYBUE was diarrhea (15%).

Common Adverse Reactions

Adverse reactions that occurred in Study 1 in at least 5% of patients treated with DAYBUE and were at least 2% more frequent than in patients on placebo are presented in the table below.

Adverse Reactions in at Least 5% of Patients

Treated With DAYBUE and at Least 2% Greater than Placebo in Study 1

mother’s clinical need for DAYBUE and any potential adverse effects on the breastfed infant from DAYBUE or from the underlying maternal condition.

Pediatric Use

The safety and effectiveness of DAYBUE for the treatment of Rett syndrome have been established in pediatric patients aged 2 years and older. The safety and effectiveness of DAYBUE for the treatment of Rett syndrome in pediatric patients 5 years of age and older was established in Study 1, which included 108 pediatric patients age 5 to less than 12 years of age and 47 pediatric patients age 12 to less than 17 years of age. Use of DAYBUE in patients 2 to 4 years of age is supported by evidence from Study 1 and pharmacokinetic and safety data in 13 pediatric patients 2 to 4 years of age treated with DAYBUE for 12 weeks.

Safety and effectiveness in pediatric patients less than 2 years of age have not been established.

Geriatric Use

Clinical studies of DAYBUE did not include patients 65 years of age and older to determine whether or not they respond differently from younger patients. This drug is known to be substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.

Renal Impairment

No dedicated clinical study has been conducted to evaluate the pharmacokinetics of DAYBUE in subjects with renal impairment. Since the drug is eliminated mainly through the kidney, administration of DAYBUE to patients with moderate or severe renal impairment is not recommended.

16 Storage and Handling

Store DAYBUE in an upright position refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the child-resistant cap tightly closed. Discard any unused DAYBUE oral solution after 14 days of first opening the bottle.

17 PATIENT COUNSELING INFORMATION

Advise the caregiver or patient to read the FDAapproved patient labeling (Patient Information).

Pediatric Patients With Rett Syndrome 2 to 4 Years of Age

In an open-label study in pediatric patients 2 to 4 years of age with Rett syndrome, a total of 13 patients received DAYBUE for at least 12 weeks and 9 patients received DAYBUE for at least 6 months. Adverse reactions in pediatric patients 2 to 4 years of age treated with DAYBUE were similar to those reported in adult and pediatric patients 5 years of age and older with Rett syndrome in Study 1.

7 DRUG INTERACTIONS

Effect of DAYBUE on Other Drugs

Trofinetide is a weak CYP3A4 inhibitor; therefore, plasma concentrations of CYP3A4 substrates may be increased if given concomitantly with DAYBUE. Closely monitor when DAYBUE is used in combination with orally administered CYP3A4 sensitive substrates for which a small change in substrate plasma concentration may lead to serious toxicities.

Plasma concentrations of OATP1B1 and OATP1B3 substrates may be increased if given concomitantly with DAYBUE. Avoid the concomitant use of DAYBUE with OATP1B1 and OATP1B3 substrates for which a small change in substrate plasma concentration may lead to serious toxicities.

8 USE IN SPECIFIC POPULATIONS

Pregnancy

Risk Summary

There are no adequate data on the developmental risks associated with the use of DAYBUE in pregnant women. No adverse developmental effects were observed following oral administration of trofinetide to pregnant animals at doses associated with plasma exposures below those used clinically.

Lactation

Risk Summary

There is no information regarding the presence of trofinetide or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the

DAYBUE Administration

Advise the caregiver or patient that DAYBUE may be given orally or via gastrostomy (G) tube; doses administered via gastrojejunal (GJ) tubes must be administered through the G-port. DAYBUE may be taken with or without food.

Instruct the caregiver or patient to obtain a calibrated measuring device, such as an oral syringe or oral dosing cup, from the pharmacy to measure and deliver the prescribed dose accurately. A household measuring cup is not an adequate measuring device. Instruct the caregiver or patient to discard any unused DAYBUE after 14 days of first opening the bottle.

Diarrhea

Advise the caregiver or patient that DAYBUE can cause diarrhea. Instruct the patient to stop taking laxatives before starting DAYBUE. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed [see Warnings and Precautions]

Weight Loss

Inform the caregiver or patient that DAYBUE may cause weight loss and to notify their healthcare provider if weight loss occurs [see Warnings and Precautions]

Vomiting

Advise the caregiver or patient that DAYBUE can cause vomiting and if vomiting occurs after DAYBUE administration, do not take an additional dose, but continue with the next scheduled dose.

Storage

Keep bottles of DAYBUE oral solution upright and refrigerated before and after opening. Do not freeze [see Storage and Handling]

Marketed by: Acadia Pharmaceuticals Inc. San Diego, CA 92130 USA

©2023 Acadia Pharmaceuticals Inc. DAYBUE is a trademark of Acadia Pharmaceuticals Inc. All rights reserved. DAY-0040 03/23

Sunday, April 23, 2023

The Vision of the American Academy of Neurology is to be indispensable to our members.

The Mission of the American Academy of Neurology is to promote the highest quality patient-centered neurologic care and enhance member career satisfaction.

American Academy of Neurology 201 Chicago Avenue Minneapolis, MN 55415 USA

Phone: (800) 879-1960 (Toll Free) or (612) 928-6000 (International)

Fax: (612) 454-2744

Email: memberservices@aan.com

Website: AAN.com

AAN Chief Executive Officer: Mary E. Post, MBA, CAE

Managing Editor:  Angela M. Babb, MS, CAE, APR

Editor: Tim Streeter

Writers: Ryan Knoke, Sarah Parsons

Designer: Andrew Imholte

Photography: Will Evans

Annual Meeting Daily is published by the American Academy of Neurology.

The American Academy of Neurology’s registered trademarks and service marks are registered in the United States and various other countries around the world.

“American Brain Foundation” is a registered service mark of the American Brain Foundation and is registered in the United States.

Top Research, Speakers Spotlighted in This Morning’s Presidential Plenary Session

An impressive lineup will address attendees for the premier lectures for clinically relevant research at this morning’s Presidential Plenary Session from 9:15 a.m. to 12:00 p.m. in the Grand Ballroom: Level 3. The hugely popular session is open to all meeting attendees.

The session will be moderated by:

Natalia S. Rost, MD, MPH, FAAN, FAHA Chair, AAN Science Committee

PRESIDENTIAL LECTURE

Presidential Lecture: A Legacy of Brain Health

Orly Avitzur, MD, MBA, FAAN Tarrytown, NY

H. HOUSTON MERRITT LECTURE

The Globalization of Neurologic Education: Teaching Neurology in Krakow, Poland

Ralph F. Józefowicz, MD, FAAN University of Rochester, Rochester, NY

SIDNEY CARTER AWARD IN CHILD NEUROLOGY

Lineage, Legacy, and the Future of Child Neurology

Erika Fullwood Augustine, MD, FAAN Kennedy Krieger Institute, Baltimore, MD

ROBERT WARTENBERG LECTURE

Migraine: Then, Now, and Tomorrow: Progress Through Biology

Peter Goadsby, MD, PhD, FRS UCLA, Los Angeles, CA

What does leaving a legacy in #BrainHealth mean to you? Join the conversation at #AANAM.

Live “Fireside Chat” to Follow Presidential Plenary Session

Head over to the Research Hub in the North Lobby after the session to engage with and ask questions of plenary moderators and presenters during the live, 30-minute “Fireside Chat.”

Neurology Leaders to Hold ‘A Global Brain Health Conversation’

Building the future of brain health worldwide is a universal priority for the neurologic community. So, it’s most fitting that the AAN Annual Meeting offers ‘A Global Brain Health Conversation’ today at 1:00 p.m. at HeadTalks (Northwest Lobby A: Level 1).

In this session, leaders from the American Academy of Neurology, the European Academy of Neurology, and the World Federation of Neurology will assemble to discuss key elements and determinants of brain health globally and the collaborations necessary to advance brain health for all.

Participants include:

Students Set to Explore Exciting Career Opportunities, Network at Today’s Symposium

Medical students will have a unique opportunity to explore exciting career opportunities within neurology at today’s Medical Student Symposium: Careers in Neurology from 12:30 p.m. to 5:00 p.m. at the Omni Boston Seaport in Ensemble A, B, and D. Students will gain an understanding about careers in neurology, the various subspecialty areas in neurology, and be able to network with residents and neurologists.

The event will kick off with a luncheon, where medical students will be seated at a table with a physician and resident/fellow. Benjamin M. Greenberg, MD, FAAN, of the University of Texas Southwestern, will provide the keynote address on “Why Neurology Is Rewarding.” A lively discussion will follow with moderators leading a panel comprised of a resident, medical student, and program director through a series of questions like “What does it mean to do a residency in neurology? What are they looking for in a candidate? What if I want to do research? Other advice for getting into residency?”

For the latter portion of the event, students will meet and speak with physicians who represent 20 different neurology subspecialties who will share information about their subspecialty, their education and career paths, and how they maintain a work-life balance, before ending the day networking around such subspecialties as those in the adjacent column.

Behavioral Neurology and Neuropsychiatry

Child Neurology

Epilepsy

General Neurology

Global Neurology

Headache

Industry in Neurology

Movement Disorders

Neuroimmunology and Multiple Sclerosis

Neurocritical Care

Neurodevelopmental Disabilities

Neuroinfectious Disease

Neuromuscular

Neuro-oncology

Neuro-ophthalmology

Neuropalliative Care

Sleep

Sports Neurology

Vascular/Stroke

Women’s Neurology

Orly Avitzur, MD, MBA, FAAN President, American Academy of Neurology

David A. Evans, MBA Chair, AAN Committee on Public Engagement

Natalia S. Rost, MD, MPH, FAAN, FAHA Co-chair, AAN Committee on Public Engagement

Paul A.J.M. Boon, MD, PhD, FEAN President, European Academy of Neurology

Wolfgang Grisold, MD, FAAN President, World Federation of Neurology

Tonight We’re Going to Party Like It’s 1949!

We’ve come a long way from our founding in 1948 and the first Annual Meeting in French Lick, Indiana, in 1949! Salute your American Academy of Neurology at tonight’s festive 75th Anniversary Celebration from 7:00 p.m. to 10:00 p.m. at Boston’s Museum of Science.

Your attendee badge is your ticket into the party, so be sure to wear it (and your best AAN green attire) as we take a trip through the decades. If you wish to bring a companion (21+), you can purchase a guest ticket at Registration. Gather with friends and colleagues as you enjoy food and beverages, music, exhibitions, and more. Buses will take you to the 75th Anniversary Celebration at the Museum of Science. View the Room Locator or the mobile app for the schedule of buses departing from hotels in the AAN block and the convention center. Buses will run continuously to and from the museum and hotels throughout the evening.

SUNDAY, APRIL 23

Hot Topics in Smoldering Disease and Future Targets in Multiple Sclerosis

Monday April 24th 6:00PM EST

Doors open at 5:30PM EST, Dinner will be served

Westin Waterfront Grand Ballroom AB

1960s–1970s

The AAN Annual Meeting

Banquet. Miami Beach 1960

15th Anniversary Exhibit. Minneapolis 1963

A.B. Baker, MD, FAAN. Chicago 1968

Sidney Carter, MD, FAAN, and wife Elizabeth. Washington, DC 1969

Nelson G. Richards, MD, FAAN. Bal Harbor 1970 Richard P. Schmidt, MD, FAAN. Bal Harbor 1970

Front: Paul Yakovlev, MD, FAAN; Russel N. DeJong, MD, FAAN; Adolph L. Sahs, MD, FAAN; A.B. Baker, MD, FAAN; Rear: Joseph R. Brown, MD, FAAN; Joseph M. Foley, MD, FAAN. Boston 1973

1960s–1970s

Today’s Opening Luncheon Kicks Off Four Days of Exhibit Hall Happenings

Make your way to Exhibit Hall A & B1 today beginning at 11:30 a.m. for the always popular Opening Luncheon that will kick off four days of happenings you won’t want to miss! Open daily from 11:30 a.m. to 4:00 p.m. through Wednesday (and through 6:00 p.m. on Monday), the Exhibit Hall promises to be jam-packed with countless opportunities to explore, discover, and connect through interactive exhibits, events, and experiences. Learn about the latest advancements in patient care, find products that add efficiencies to your practice, and gather resources that assist patients and caregivers. Building a trip to the Exhibit Hall into your Annual Meeting schedule is the only way to get new information from the diverse, neurologyfocused companies that are here to help you and your patients. Use the AAN Conferences mobile app to find more details and locations about specific exhibitors! Additionally, the Exhibit Hall gives you the opportunity to:

• Have a cup of coffee or specialty hot or iced espresso drink at the Buzz Cafes. Whether you prefer regular or decaf, vegan or half & half, there’s a coffee beverage for you!

• Relax and recharge your devices—and yourself—while connecting to colleagues from the variety of comfortable seating options and locations in the Exhibit Hall Charging Lounges. Even those on the go can charge their devices in the safety of the Charging Lockers.

• Welcome the return of the Innovation Hub with physician talks, paint and wine, and virtual reality experience!

• Discover cutting-edge technologies and therapies in the Emerging Technologies Neighborhood.

• Learn about pipeline products, new notable companies, and more at the Emerging Neurologic Care Presentation Stage.

• Enjoy food and fun at the Monday evening Networking Crawl from 4:00 p.m.–6:00 p.m. Remember to Complete Your ‘Passport’

to Win Prizes!

Remember to complete your Exhibit Hall Passport for a chance to win prizes, including a grand prize drawing of a 2024 Annual Meeting registration and a three-night stay in an AAN block hotel—compliments of the Academy. Passports are available in the Exhibit Hall. Opening Luncheon sponsored by Viatris Inc.

Mabel G. Masten, MD, FAAN. Bal Harbor 1970

Maynard M. Cohen, MD, FAAN, and wife Doris Vidaver. Bal Harbor 1970

Annual Meeting attendees were treated to a performance by the Boston Pops Orchestra. Boston 1973

Gilbert H. Glaser, MD, FAAN; Morfydd Glaser; Jane Daroff; Robert B. Daroff, MD, FAAN. Bal Harbor 1975

Rare Inspiration. Changing Lives.

Alexion is now investigating 2 new treatments for generalized myasthenia gravis (gMG).

For over 30 years, Alexion’s mission has been to deepen our understanding and transform the lives of people who are affected by rare diseases and living with devastating conditions. We bring this same steadfast commitment to patients with generalized myasthenia gravis (gMG).

ALXN2050. The ExpanD Study is a phase 2 study evaluating the oral investigational medication ALXN2050 for the treatment of gMG.

ALXN2050 is an inhibitor of complement factor D, a component of the alternative pathway, which is being investigated as a novel mechanism of action for the treatment of adults with gMG.

ALXN1720. The Prevail Study is a phase 3 study evaluating Alexion’s new complement component C5 inhibitor, gefurulimab (ALXN1720), for the treatment of adults with gMG.

Gefurulimab is developed for selfadministration through once-weekly subcutaneous injection, which would provide patients with more autonomy and greater flexibility to benefit from a mechanism of action that is well established.

NCT05218096

NCT05556096

Saniya Pervin @PervinSaniya

Kick starting Day 1 at #AANAM with the plenary session “Controversies in #Neurology ” #neurotwitter @AANmember

ThienThanh Nguyen, MD @ThienThanhNgu15

Starting Day 1 with Enhanced resident Leadership program at #AANAM #neurotwitter @AANmember @NeuroUky

Annika Ehrlich, MS, FNP-C, CNRN, AQH @EhrlichNP

Neurologist and Headache specialist @DrHopeMO kicking off @AANmember #AANAMso excited to start the day, my first time attending an in person annual meeting!!!

Bert Vargas @BertVargas

In my room planning the day @ #AANAM while rocking those @AANmember socks!

Shravan Sivakumar @sshravanMD

Starting #AANAM #boston with a golden ticket! #neurotwitter @umassneurology

Anishee Undavia, MD @AnisheeShah

In a new era where instead of stating disclosures the speaker first affirms that they did not use chat gpt #neurotwitter #aanam

2023–2025 Officers and Board Members Approved at Business Meeting

AAN members elected the slate of officers and directors nominated for the 2023–2025 term at Saturday’s Business Meeting. They will begin their terms on April 28.

Officers

• Carlayne E. Jackson, MD, FAAN, President

• Natalia S. Rost, MD, MPH, FAAN, FAHA, President Elect

• Janis M. Miyasaki, MD, MEd, FRCPC, FAAN, Vice President

• Sarah M. Benish, MD, FAAN, Secretary

• Charles C. Flippen II, MD, FAAN, Treasurer

• Orly Avitzur, MD, MBA, FAAN, Immediate Past President

Directors

• Wayne E. Anderson, DO, FAHS, FAAN

• Jennifer Bickel, MD, FAAN*

• Gregory J. Esper, MD, MBA, FAAN*

• Larry B. Goldstein, MD, FAAN, FAHA

• Lily Jung Henson, MD, MMM, FAAN

• Shannon M. Kilgore, MD, FAAN

• Jeffrey C. McClean II, MD, FAAN*

• Bruce I. Ovbiagele, MD, MSc, MAS, MBA, MLS, FAAN

• José H. Posas, MD, FAAN*

The following additional directors will serve as ex officio directors:

• Bruce H. Cohen, MD, FAAN, Chair, Advocacy Committee/ex officio

• Brad C. Klein, MD, MBA, FAAN, Chair, Medical Economics and Practice Committee/ex officio

• José G. Merino, MD, MPhil, FAHA, FAAN, Editor-in-Chief of Neurology ® /ex officio

• Nimish A. Mohile, MD, FAAN*, Chair, Diversity, Equity, and Inclusion Committee/ex officio

• Maisha T. Robinson, MD, MSHPM, FAAN, Chair, Member Engagement Committee/ ex officio

• Mary E. Post, MBA, CAE, Chief Executive Officer/ex officio, non-voting

*New to the Board

The Academy is comprised of two legal entities, the AAN and the AAN Institute. Most of the elected members of the AAN Board of Directors also serve ex officio on the Board of Directors of the AAN Institute, which includes an independent secretarytreasurer and additional members who serve in ex officio capacities. The AAN Institute Board of Directors will include the following additional members:

• Brett M. Kissela, MD, MS, FAHA, FAAN, Secretary-Treasurer

• Paul M. George, MD, PhD, FAAN, Chair, Science Committee/ex officio

• Lyell K. Jones, Jr., MD, FAAN, Chair, Quality Committee/ex officio

• José G. Merino, MD, MPhil, FAHA, FAAN, Editor-in-Chief of Neurology ® /ex officio

• Joseph I. Sirven, MD, FAAN, Chair, Education Committee/ex officio

• Mary E. Post, MBA, CAE, Chief Executive Officer/ex officio, non-voting

These amendments to the AAN Bylaws were approved at the Business Meeting:

• Adding the Chair of the DEI Committee to the AAN Board in Article IV, Section 1

• Replacing all mentions of “Executive Director” with “CEO” throughout the Bylaws

• Replacing “Chairman” with “Chair” in Article IV, Section 5

For more information, contact Karen Kasmirski, Senior Governance Coordinator, at kkasmirski@aan.com.

Carlayne E. Jackson, MD, FAAN, presenting at the AAN Business Meeting.

Wake Up to Java, Juice, & Jobs on Monday

Annual Meeting attendees won’t want to miss a flavorful new career event Monday morning from 7:00 a.m. to 9:00 a.m. in Room 160 ABC in the Boston Convention and Exhibition Center.

Java, Juice, & Jobs, sponsored by the Neurology Career Center, features networking opportunities with your peers and neurology hiring managers, interactive career-related stations, one-on-one career advice from seasoned AAN members, and free giveaways. Enjoy the free breakfast and specialty coffee drinks as you start your day at this fun event offering something for everyone. For more information, visit AAN.com/AMProgram and search for Java, Juice, & Jobs.

New Daylong Event Offers Solutions to Academic, Private Practice Administrators

The first Annual Meeting Business Administrator Day begins at 8:00 a.m. Monday, in room 151AB. This unique event, themed “Resilience and Reinvention in the Post-pandemic Era,” promises to be full of actionable content, engaging dialogue, and network building. Topics will include building team resilience, reinventing staffing solutions, and wellness for business administrators. At the end of the program, administrators will have the opportunity to unwind with their peers over wine and appetizers at an exclusive reception.

Visit Awards Display in Poster Hall

Visit the AAN awards display in the Poster Hall, which will feature a red-carpet backdrop for photos and a vibrant display of award winner names. Be sure to share your photos on social media using #AANAM and #AANScience. The Poster Hall is open starting today and will close on Thursday when the final poster session concludes at 12:45 p.m.

Poster Hall Opens Today, Features Latest Research

The popular Annual Meeting staple—the Poster Hall—kicks off today in Exhibit Hall B2 and will run daily. The hall will feature all digital displays with 14 author standby opportunities for questions taking place today through Wednesday from 8:00 a.m. to 9:00 a.m., 11:45 a.m. to 12:45 p.m., and 5:30 p.m. to 6:30 p.m., and on Thursday from 8:00 a.m. to 9:00 a.m. and 11:45 a.m. to 12:45 p.m. To help you easily navigate your way to the breakthrough research of most interest to you, each of the sessions in this year’s hall are grouped in topic-related “neighborhoods.”

prescription medicine for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older1

Get Started With SKYCLARYS:

Submit a Start Form today at ReataREACH.com. Reata REACH is here to support your eligible patients with FA. Scan the QR code to start now.

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

Elevation of Aminotransferases: Treatment with SKYCLARYS can cause an elevation in hepatic transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]). Monitor ALT, AST, and total bilirubin prior to initiation of SKYCLARYS, every month for the first 3 months of treatment, and periodically thereafter.

Elevation of B-Type Natriuretic Peptide: Treatment with SKYCLARYS can cause an increase in B-type natriuretic peptide (BNP), a marker of cardiac function. Elevations in BNP may indicate cardiac failure and should prompt an evaluation of cardiac function. Check BNP prior to initiation of SKYCLARYS. Monitor patients for the signs and symptoms of fluid overload.

Lipid Abnormalities: Treatment with SKYCLARYS can cause changes in cholesterol. Assess lipid parameters prior to initiation of SKYCLARYS and monitor periodically during treatment.

ADVERSE REACTIONS

Adverse reactions reported in 10% or more of patients and greater than placebo were elevated liver enzymes (AST/ALT) (37%), headache (37%), nausea (33%), abdominal pain (29%), fatigue (24%), diarrhea (20%), musculoskeletal pain (20%), oropharyngeal pain (18%), influenza (16%), vomiting (16%), muscle spasms (14%), back pain (13%), decreased appetite (12%), rash (10%).

To report SUSPECTED ADVERSE REACTIONS, contact Reata Pharmaceuticals, Inc. at 1-800-314-3934 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

SKYCLARYS is indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.

For additional information about SKYCLARYS, please see the Brief Summary on the following page and the full Prescribing Information at hcp.SKYCLARYS.com.

BRIEF SUMMARY

SKYCLARYS™ (omaveloxolone) capsules, for oral use

1 INDICATIONS AND USAGE

SKYCLARYS is indicated for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Testing Before Initiating SKYCLARYS and Monitoring to Assess Safety

Obtain ALT, AST, bilirubin, BNP, and lipid parameters prior to initiating SKYCLARYS and during treatment [see Warnings and Precautions (5.1, 5.2, 5.3)]

2.2 Recommended Dosage

The recommended dosage of SKYCLARYS is 150 mg (3 capsules) taken orally once daily.

• Administer SKYCLARYS on an empty stomach at least one hour before eating [see Clinical Pharmacology (12.3)]

• Swallow SKYCLARYS capsules whole. Do not open, crush, or chew.

2.3 Missed Doses

If a dose of SKYCLARYS is missed, take the next dose at its scheduled time the following day. A double dose should not be taken to make up for a missed dose.

2.4 Recommendations for Concomitant Use with Strong or Moderate CYP3A4 Inhibitors and Inducers

The recommended dosage for concomitant use of SKYCLARYS with cytochrome P450 (CYP) 3A4 inhibitors and inducers are described in Table 1 [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]

Table 1: Recommended Dosage of SKYCLARYS with Concomitant Use of CYP3A4 Inhibitors and Inducers

5.3 Lipid Abnormalities

Treatment with SKYCLARYS can cause changes in cholesterol. In Study 1, 29% of patients treated with SKYCLARYS reported elevated cholesterol above ULN at one or more time points. Mean increases were observed within 2 weeks of initiation of SKYCLARYS and returned to baseline within 4 weeks of discontinuing treatment. A total of 16% of patients treated with SKYCLARYS had an increase in low-density lipoprotein cholesterol (LDL-C) from baseline, compared to 8% of patients who received placebo. The mean increase in LDL-C for all SKYCLARYS-treated patients was 23.5 mg/dL at 48 weeks. A total of 6% of patients treated with SKYCLARYS had decreases in high-density lipoprotein cholesterol (HDL-C) from baseline compared to 4% of patients who received placebo.

The mean decrease in HDL-C for all SKYCLARYS-treated patients was 5.3 mg/dL at 48 weeks.

Assess lipid parameters prior to initiation of SKYCLARYS and monitor periodically during treatment.

Manage lipid abnormalities according to clinical guidelines.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described in greater detail in other labeling sections:

• Elevation of aminotransferases [see Warnings and Precautions (5.1)]

• Elevation of BNP [see Warnings and Precautions (5.2)]

• Lipid abnormalities [see Warnings and Precautions (5.3)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of SKYCLARYS 150 mg once daily has been evaluated in 165 patients with Friedreich’s ataxia, including 137 patients exposed for at least 48 weeks, and 125 patients exposed for at least 96 weeks.

The most common adverse reactions in Study 1 (≥20% and greater than placebo) were elevated liver enzymes (AST/ALT), headache, nausea, abdominal pain, fatigue, diarrhea, and musculoskeletal pain. Table 3 shows the adverse reactions that occurred in 10% or more of patients treated with SKYCLARYS and greater than placebo.

dose range-finding study, oral administration of omaveloxolone at doses up to 30 mg/kg/day to pregnant rats throughout organogenesis produced increases in post-implantation loss and resorptions, resulting in a decrease in viable fetuses, and reduced fetal weight at the highest dose tested. At the highest dose tested in the pivotal study (10 mg/kg/day), plasma exposure (AUC) was approximately 5 times that in humans at the recommended human dose (RHD) of 150 mg/day.

Oral administration of omaveloxolone (0, 3, 10, or 30 mg/kg/day) to pregnant rabbits throughout organogenesis resulted in increased embryofetal mortality and skeletal variations and reduced fetal weight at the highest dose tested, which was associated with maternal toxicity. At the no-effect dose for adverse effects on embryofetal development (10 mg/kg/day), plasma exposure was less than that in humans at the RHD.

Oral administration of omaveloxolone (0, 1, 3, or 10 mg/kg/day) throughout pregnancy and lactation resulted in an increase in stillbirths and impaired neurobehavioral function (increased locomotor activity and learning and memory deficits) in offspring at all doses, reduced body weight in offspring at all but the lowest dose tested, and delayed sexual maturation (males), increased postnatal mortality, and impaired reproductive performance in offspring at the highest dose tested. A no-effect dose for adverse effects on pre- and postnatal development was not identified. Plasma exposure (AUC) at the lowest dose tested was less than that in humans at the RHD.

8.2 Lactation

Risk Summary

There are no data on the presence of omaveloxolone or its metabolites in human milk. The effects on milk production and the breastfed infant are unknown. Omaveloxolone was excreted in the milk of lactating rats following oral administration. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SKYCLARYS and any potential adverse effects on the breastfed infant from SKYCLARYS or from the underlying maternal condition.

8.3 Females and Males of Reproductive Potential

• Reduce the dosage of SKYCLARYS to 50 mg once daily with close monitoring for adverse reactions.

• If adverse reactions emerge, coadministration with strong CYP3A4 inhibitors should be discontinued.

• Reduce the dosage of SKYCLARYS to 100 mg once daily with close monitoring for adverse reactions.

• If adverse reactions emerge, further reduce the dosage of SKYCLARYS to 50 mg once daily. Strong or Moderate CYP3A4 inducer Recommended to avoid concomitant use.

2.5 Recommended Dosage for Patients with Hepatic Impairment

The recommended dosage for patients with hepatic impairment are described in Table 2 [see Use in Specific Populations (8.6)]

Table 2: Recommended Dosage in Patients with Hepatic Impairment

Table 3: Adverse Reactions Reported in 10% or More of Patients Treated with SKYCLARYS and Greater than Placebo (Study 1)

SKYCLARYS may decrease the efficacy of hormonal contraceptives [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. Advise patients to avoid concomitant use with combined hormonal contraceptives (e.g., pill, patch, ring), implants, and progestin only pills. Counsel females using hormonal contraceptives to use an alternative contraceptive method (e.g., non-hormonal intrauterine system) or additional non-hormonal contraceptive (e.g., condoms) during concomitant use and for 28 days after discontinuation of SKYCLARYS.

8.4 Pediatric Use

The safety and effectiveness of SKYCLARYS for the treatment of Friedreich’s ataxia have been established in pediatric patients aged 16 years and older. Use of SKYCLARYS for this indication is supported by evidence from one adequate and well-controlled study (Study 1) in adults and in pediatric patients aged 16 years and older [see Clinical Studies (14)]

Safety and effectiveness of SKYCLARYS have not been established in pediatric patients less than 16 years of age.

8.5 Geriatric Use

Clinical studies of SKYCLARYS in Friedreich’s ataxia did not include patients aged 65 and over. No data are available to determine whether they respond differently than younger adult patients.

8.6 Hepatic Impairment

Omaveloxolone plasma exposure is increased in patients with moderate or severe hepatic impairment (Child-Pugh Class B and C) [see Clinical Pharmacology (12.3)]. Avoid treatment with SKYCLARYS in patients with severe hepatic impairment, including those who develop severe hepatic impairment. If hepatic function improves to moderate impairment, mild impairment, or normal function, initiation of SKYCLARYS treatment at the approved recommended dosage may be considered. For patients with moderate hepatic impairment, a reduced dosage is recommended with close monitoring for adverse reactions [see Dosage and Administration (2.5)]. For patients with mild hepatic impairment (Child-Pugh Class A), no dose adjustments are recommended.

9 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Elevation of Aminotransferases

• 100 mg once daily with close monitoring for adverse reactions

• Consider lowering to 50 mg once daily if adverse reactions emerge

3 DOSAGE FORMS AND STRENGTHS

SKYCLARYS capsules contain 50 mg of omaveloxolone, and are supplied as opaque hard capsules having a light green body and blue cap, imprinted with “RTA 408” in white ink on the body and “50” in white ink on the cap.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Elevation of Aminotransferases

Treatment with SKYCLARYS can cause an elevation in hepatic transaminases (ALT and AST). In Study 1 [see Clinical Studies (14)], the incidence of elevations of ALT or AST above 5 times and 3 times the upper limit of normal (ULN) was 16% and 31%, respectively, in patients treated with SKYCLARYS. There were no cases of concomitant elevation of transaminases and total bilirubin observed in Study 1. Maximum increases in ALT and AST occurred within 12 weeks after starting SKYCLARYS. Increases in serum aminotransferases were generally asymptomatic and reversible following discontinuation of SKYCLARYS. Patients with clinically significant liver disease were excluded from Study 1.

Monitor ALT, AST, and total bilirubin prior to initiation of SKYCLARYS, every month for the first 3 months of treatment, and periodically thereafter. If transaminases increase to levels greater than 5 times the ULN, or greater than 3 times the ULN with evidence of liver dysfunction (e.g., elevated bilirubin), immediately discontinue SKYCLARYS and repeat liver function tests as soon as possible. If transaminase levels stabilize or resolve, SKYCLARYS may be reinitiated with an appropriate increased frequency of monitoring of liver function [see Adverse Reactions (6.1) and Use in Specific Populations (8.6)]

5.2 Elevation of B-Type Natriuretic Peptide

Treatment with SKYCLARYS can cause an increase in BNP, a marker of cardiac function. In Study 1, a total of 14% of patients treated with SKYCLARYS had an increase from baseline in BNP and a BNP above the ULN (100 pg/mL), compared to 4% of patients who received placebo. The incidence of elevation of BNP above 200 pg/mL was 4% in patients treated with SKYCLARYS. Cardiomyopathy and cardiac failure are common in patients with Friedreich’s ataxia. Patients were excluded from Study 1 if they had BNP levels > 200 pg/mL prior to study entry, or a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease, with the exception of mild to moderate cardiomyopathy associated with Friedreich’s ataxia [see Adverse Reactions (6.1)] Whether the elevations in BNP in Study 1 are related to SKYCLARYS or cardiac disease associated with Friedreich’s ataxia is unclear.

Elevations in BNP may indicate cardiac failure and should prompt an evaluation of cardiac function. Check BNP prior to initiation of SKYCLARYS. Monitor patients for the signs and symptoms of fluid overload, such as sudden weight gain (3 pounds or more of weight gain in one day, or 5 pounds or more of weight gain in a week), peripheral edema, palpitations, and shortness of breath. If signs and symptoms of fluid overload develop, worsen, or require hospitalization, evaluate BNP and cardiac function, and manage appropriately. Management of fluid overload and heart failure may require discontinuation of SKYCLARYS.

Laboratory Abnormalities

In addition to elevated liver enzymes, additional laboratory abnormalities include elevation of BNP and lipid abnormalities [see Warnings and Precautions (5.1, 5.2, 5.3)]

7 DRUG INTERACTIONS

7.1 Effect of Other Drugs on SKYCLARYS

CYP3A4 Inhibitors

Omaveloxolone is a CYP3A4 substrate. Concomitant use of SKYCLARYS with moderate or strong CYP3A4 inhibitors is expected to result in clinically significant increased exposure of omaveloxolone [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions. Avoid concomitant use of SKYCLARYS with moderate or strong CYP3A4 inhibitors. If use cannot be avoided, dosage modifications are recommended [see Dosage and Administration (2.4)]

CYP3A4 Inducers

Omaveloxolone is a CYP3A4 substrate. Concomitant use of SKYCLARYS with moderate or strong CYP3A4 inducers may significantly decrease exposure of omaveloxolone [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of SKYCLARYS. Avoid concomitant use of SKYCLARYS with moderate or strong CYP3A4 inducers.

7.2 Effect of SKYCLARYS on Other Drugs

CYP3A4 and CYP2C8 Substrates

Omaveloxolone is a weak inducer of CYP3A4 and CYP2C8. Concomitant use with SKYCLARYS can reduce the exposure of CYP3A4 and CYP2C8 substrates which may reduce the activity of these substrates [see Clinical Pharmacology (12.3)]. Refer to the prescribing information of substrates of CYP3A4 and CYP2C8 for dosing instructions if used concomitantly with SKYCLARYS and monitor for lack of efficacy of the concomitant treatment.

Hormonal Contraceptives

Omaveloxolone is a weak CYP3A4 inducer [see Clinical Pharmacology (12.3)]. Concomitant use with SKYCLARYS may reduce the efficacy of hormonal contraceptives. Advise patients to avoid concomitant use with combined hormonal contraceptives (e.g., pill, patch, ring), implants, and progestin only pills [see Use in Specific Populations (8.3)]

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no adequate data on the developmental risks associated with the use of SKYCLARYS in pregnant women. In animal studies, administration of omaveloxolone during pregnancy or throughout pregnancy and lactation produced evidence of developmental toxicity (embryofetal mortality and growth impairment, and mortality, growth impairment, and neurobehavioral deficits in offspring) at plasma exposures similar to or less than exposures in humans (see Animal Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.

Data

Animal Data

Oral administration of omaveloxolone (0, 1, 3, or 10 mg/kg/day) to pregnant rats throughout organogenesis resulted in no adverse effects on embryofetal development; however, in a

Inform patients that elevation in aminotransferases have occurred in patients treated with SKYCLARYS. Liver function tests will be performed prior to initiating SKYCLARYS, every month for the first 3 months of treatment, and periodically thereafter as needed [see Warnings and Precautions (5.1)]

Fluid Overload

Inform patients that elevations in BNP, a marker of cardiac function, have occurred in patients treated with SKYCLARYS. BNP will be performed prior to initiating SKYCLARYS and if signs and symptoms of fluid overload occur, such as sudden weight gain, peripheral edema, palpitations, and shortness of breath. Advise patients to contact their healthcare provider if signs and symptoms of fluid overload develop [see Warnings and Precautions (5.2)]

Lipid Abnormalities

Inform patients that treatment with SKYCLARYS has been associated with increases in LDL cholesterol and decreases in HDL cholesterol. Cholesterol will be assessed prior to starting SKYCLARYS and monitored periodically during treatment [see Warnings and Precautions (5.3)]

Drug Interactions

Advise patients to discuss all medications they are taking, including other prescription medications, non-prescription medications, or herbal products (e.g., St. John’s Wort) with their healthcare provider [see Drug Interactions (7)]

Pregnancy

Advise women to notify their healthcare provider if they become pregnant or intend to become pregnant during SKYCLARYS therapy [see Use in Specific Populations (8.1)]

Females of Reproductive Potential

Counsel females using hormonal contraceptives to use an alternative contraceptive method (e.g., non-hormonal intrauterine system) or additional non-hormonal contraceptive (e.g., condoms) during concomitant use and for 28 days after discontinuation of SKYCLARYS [see Drug Interactions (7.2) and Use in Specific Populations (8.3)]

Administration

Advise patients to take SKYCLARYS on an empty stomach at least 1 hour before eating [see Dosage and Administration (2.2)]

Swallow SKYCLARYS capsules whole. Do not open, crush, or chew. Advise patients that if a dose of SKYCLARYS is missed to not to double their dose or take more than the prescribed dose [see Dosage and Administration (2.3)]

Advise patients to avoid grapefruit juice and grapefruit while they are taking SKYCLARYS [see Drug Interactions (7.1)]

Manufactured for Reata Pharmaceuticals, Inc., Plano, TX 75024 USA

SKYCLARYS is a trademark of Reata Pharmaceuticals Holdings, LLC, used under license by Reata Pharmaceuticals, Inc., Plano, TX 75024 USA

Copyright© 2023, Reata Pharmaceuticals, Inc., Plano, TX 75024 USA

All rights reserved

© 2023 Reata Pharmaceuticals, Inc. All Rights Reserved. SKYCLARYS, REATA, and their logos are trademarks of Reata Pharmaceuticals, Inc. US-SKY-2200013 03/2023

American Brain Foundation Booth Highlights Research Grant Opportunities and Ways to Support Them

Stop by the American Brain Foundation booth in the North Lobby from 7:00 a.m. to 5:30 p.m. through Thursday to learn about all the available research grant opportunities for 2024—and about the work currently receiving funding—or to donate to support the critical need for further research. Proudly show your support for the power of research with a donation for a t-shirt or other exclusive items.

Founded by its research partner, the American Academy of Neurology, the American Brain Foundation has been investing in research for improved prevention, treatment, and cures for neurologic diseases and disorders for over 30 years. Our focus on funding research across the full spectrum of disorders recognizes the interconnectedness of brain diseases and supports innovation through research by the best and brightest in the field of neurology. By examining the whole brain, we get the whole picture, and we know that when we cure one brain disease, we will cure many.

Industry Roundtable Members Add Significant Value to the Annual Meeting Experience

The AAN has long recognized the value of collaborating with industry, and the Industry Roundtable (IRT) is the AAN’s corporate membership program for companies wishing to deepen their relationship with the Academy to share vision, intellect, and financial resources in the mutual pursuit of improved quality of patient care.

While the IRT is active year-round, member companies are particularly engaged at the AAN Annual Meeting, working jointly with the Academy to improve the Annual Meeting experience for all attendees through the valuable support of continuing medical education courses, inkind donations for workshops, contribution of high-quality research to the scientific program, sponsorship of the Run/Walk for Brain Research, and investment in the future of neurology by supporting the AAN Leadership Development Programs. To learn more about the Industry Roundtable and how your company can deepen its engagement with the AAN, please visit the Industry Room at the convention center.

THANK YOU TO THE FOLLOWING 2023 INDUSTRY ROUNDTABLE MEMBERS*

$50,000 Members

AbbVie

ACADIA Pharmaceuticals

Alexion Pharmaceuticals

argenx

Bristol Myers Squibb

Eisai

Eli Lilly and Company

EMD Serono

Genentech

Horizon Therapeutics

Lundbeck

Neurocrine Biosciences

Novartis Pharmaceuticals

Novo Nordisk

Pfizer

Sanofi

SK Life Science

Supernus Pharmaceuticals

Teva

TG Therapeutics

UCB, Inc.

$40,000 Members

Ionis Pharmaceuticals

Medtronic

$25,000 Members

Alnylam Pharmaceuticals

Amneal Specialty, a division of Amneal Pharmaceuticals

Avion Pharmaceuticals

Axsome Therapeutics

Azurity Pharmaceuticals

Biogen

Biohaven

Harmony Biosciences

Illumina

Impel Pharmaceuticals

IPSEN Biopharmaceuticals

Jazz Pharmaceuticals

Otsuka America

Sage Therapeutics

Satsuma Pharmaceuticals

Takeda Pharmaceuticals

$10,000 Members

Cerevel Therapeutics

PTC Therapeutics

Siemens Healthineers

Viatris

Xenon Pharmaceuticals

*As of March 13, 2023

Today’s Invited Science Focuses on Multiple Sclerosis

Today’s Invited Science Session from 3:30 p.m. to 5:30 p.m. on multiple sclerosis will feature authors giving encore presentations of top abstracts presented at subspecialty meetings. The session is presented in partnership with Americas Committee for Treatment and Research in Multiple Sclerosis. Select abstracts will emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of multiple sclerosis with the overall goal of developing more effective prevention and treatment.

Abstracts and authors include:

Psychiatric Morbidity in Multiple Sclerosis During the Prodromal Period

3:30 p.m.–3:50 p.m.

Anibal Chertcoff

Quantitative Spinal Cord Magnetic Resonance Imaging and Its Relationship with Clinical Outcomes in Multiple Sclerosis

3:50 p.m.–4:10 p.m.

Lisa Eunyoung Lee

Randomized Clinical Trial of Intermittent Calorie Restriction in People with Multiple Sclerosis: Effects on Immunometabolic and Cognitive Measures

4:10 p.m.–4:30 p.m.

Laura M. Piccio

Radiological Characterization of Cortical Lesions in Progressive Multifocal Leukoencephalopathy

4:30 p.m.–4:50 p.m.

Sarita Walvekar

EBV Epidemiology in Different Populations

4:50 p.m.–5:10 p.m.

Marianna Cortese, MD, PhD

A Comparative Effectiveness Trial of Telephone-Delivered Cognitive Behavioral Therapy, Modafinil, and Combination Therapy of Both Interventions for Fatigue in Multiple Sclerosis: Primary Results From the COMBO-MS Trial

5:10 p.m.–5:30 p.m.

Tiffany Braley, MD

Find Discounts and Giveaways at the Continuum Booth

Continuum: Lifelong Learning in Neurology ® is the AAN’s premier education and CME journal, and if you miss their booth this week, you’ll be missing some super savings and fun freebies! Stop by the Continuum ® booth in the North Lobby to receive a 15-percent discount on top of the already-discounted AAN member price for subscribing to this esteemed journal that publishes six times a year and also includes Continuum ® Audio. You also can order back issues with free shipping to your address. And as always, there will be some giveaways—if you get there before the supply runs out!

Artificial Intelligence Is Focus of this Afternoon’s Hot Topics in Clinical Practice Course

Join your colleagues in room 104AB between 1:00 p.m. and 3:00 p.m. for what is sure to be a riveting examination of artificial intelligence as it relates to neurology. Hot Topics in Clinical Practice: Artificial Intelligence will be led by director Andrew Mebane Southerland, MD, FAAN, who will discuss the various ways that artificial intelligence and machine learning tools might augment the clinical practice of neurology, including both current and future applications, potential benefits and pitfalls, and a proposed curriculum for preparing the neurology workforce for the integration of AI into neurologic practice.

Daily Reminders

For easy access to meeting links, visit AAN.com/QuickLinks.

Attendee Lunches

Attendee lunches are served from 11:00 a.m. to 1:00 p.m. in the Poster Hall, Exhibit Hall B2.

Submit Evaluations for Annual Meeting

CME

Complete your evaluations to get your CME credits by May 15, 2023 (or March 1, 2024 with Annual Meeting On Demand) by using the AAN Conferences mobile app or by visiting AAN.com/AMCME. Transcripts will be available upon evaluation submission. AAN members can also access their transcript via NeuroTracker™ at AAN.com/NeuroTracker.

Program Slides Available Online

Slides are available online only at AAN.com/Materials or through the AAN Conferences mobile app. You can access program materials through March 1, 2024.

(Please note that availability of materials is at the discretion of the specific speaker. Not all sessions will have materials.)

AANTV Studio

Stop by the AANTV Studio in the North Lobby, where you can witness live interviews being recorded for later broadcast accessible on the virtual platform, TV monitors around the convention center, and on AAN.com and YouTube. The AANTV Studio is sponsored by the AAN Family of Publications.

Want More Time to View Programs?

Add Annual Meeting On Demand to your registration to extend your access to session recordings through March 1, 2024, at a 50-percent discount Check the back of your badge to see if you already have Annual Meeting On Demand. If not, head to Registration or email aanamsupport@cmrus.com by May 15, 2023, to upgrade.

Safety and COVID-19 Protocols

The AAN continues to encourage attendees to practice safe measures to stop the spread of COVID-19, including using social distancing, testing when appropriate, taking recommended actions when symptomatic or having tested positive, and wearing a mask if you choose. We will continue to follow best practices recommended by the Centers for Disease Control and Prevention and abide by any legal mandates and recommendations from government officials.

View all conference guidelines at AAN.com/ConfGuidelines.

Attending the 75th Anniversary Celebration Tonight?

Shuttles will be provided from all regular shuttle stops and the convention center’s North Lobby entrance to the Museum of Science every 10–15 minutes. Return service will be provided at the conclusion of the event. The final departure will take place no later than 10:30 p.m. Be sure you have your attendee badge on you, as it’s your ticket in!

Shuttles

Shuttles depart and drop off from the convention center Southeast entrances on Level 0 (near Registration) or Level 1 (near Academic Hub) every 15–30 minutes throughout the day and drop off at AAN conference hotels. See more information in the AAN Conferences mobile app or Room Locator. Questions? Visit the Shuttle Help Desk or Meeting Information. Use the QR code to see where your shuttle is.

Access Past Content

Conference attendees have access to the virtual platform through May 15, 2023. Visit AAN.com/VirtualAM and use your 6-digit ID and password to log in. It may take up to 48 hours after course completion for content to become available online.

Check out Today’s Hub Highlights for Collaborative Learning

Step outside the traditional classroom and into the world of unconventional learning with eight Hub areas. Each Hub offers unique educational and networking opportunities. Engage in collaborative learning, gain actionable tools for your patients and career, and find your community. Here are today’s highlights:

ACADEMIC HUB

Southeast Lobby: Level 1

Transforming Transition: Lessons Learned about Transitioning Youth to Adult Neurology Care

1:00 p.m.–1:45 p.m.

The Child Neurology Foundation has been a leading voice on transition of care issues for more than a decade. Representatives from two grantee academic institutions, Lurie Children’s Hospital and Boston Children’s Hospital, will share highlights from quality improvement projects their institutions have been tackling for the past year. Child Neurology Foundation staff will be available to provide guidance on applying for the next grant cycle.

“Genius Is Talent on Fire”: Finding the Talent, Nurturing Genius

4:00 p.m.–4:45 p.m.

Kathleen M. Shannon, MD, FAAN, and Cynthia L. Comella, MD, FAAN, will cover strategies to find applicants whose mission and vision align with and enrich those of the department with a special focus on those who will enrich the culture and diversity of the program.

INNOVATION HUB

Exhibit Hall B1

Cognition and Call of Duty: Video Games as a Complex Cognitive Task

12:15 p.m.–12:45 p.m.

James R. Bateman III, MD, will cover the neurologic tasks involved in playing this popular game.

Daily Paint and Wine Sessions

12:00 p.m. and 2:00 p.m.

These sessions fill fast, so come early to reserve your spot!

HEADTALKS

Northwest Lobby A: Level 1

EEG Talk

2:00 p.m.–2:45 p.m.

Join this discussion about EEG readings with hosts from the beloved EEG video podcast “EEG Talk,” Fabio Nascimento, MD, and Brandon Westover, MD. Learn about EEG spectrograms: from how they work to their application in clinical EEG reading.

Standing on the Shoulders of Giants

3:00 p.m.–3:45 p.m.

Claire Henchcliffe, MD, PhD, FAAN, will take us on a journey through her neurology career and highlight contributions she has made to the evolution of the field. This series continues tomorrow at 11:00 a.m. with Merit E. Cudkowicz, MD, MSc.

PRACTICE AND POLICY HUB

Northwest Lobby: Level 2

Getting Paid for Non-face-to-face Codes

3:30 p.m.–4:15 p.m.

Neil A. Busis, MD, FAAN; Carrie Katherine Grouse, MD, FAAN; and Allan Ding Wu, MD, FAAN, will explore codes used for interactions with patients and their families outside office and telemedicine visits. They will also discuss the requirements for billing non-faceto-face codes, chronic and principal care management codes, and appropriate coding for visits via patient portal and telephone encounters.

LEADERSHIP UNIVERSITY

Room 154

Leveraging Inclusion to Mitigate Bias in Challenging Times

12:00 p.m.–1:30 p.m.

Jeffrey C. McClean II, MD, FAAN; Laraine Kaminsky; Charles C. Flippen II, MD, FAAN; Salvador Cruz-Flores, MD, FAAN; and Erika Tatiana Marulanda-Londono, MD, will discuss how bias impacts judgments and decision-making in the medical field, particularly during times of heightened stress and crises, how implementing inclusiveness practices can mitigate the impact of bias and contribute to better problem-solving, and lessons learned and good practices when applying bias interventions and implementing inclusiveness initiatives.

Shannon Comella

Henchcliffe Cudkowicz

Tools to Manage Oneself and Others During Times of Increased Pressure

2:00 p.m.–3:00 p.m.

A physician faces many difficult challenges in the present times, including but not limited to staffing changes, lingering changes due to the pandemic, and budgetary issues. Nassim Zecavati, MD, FAAN, will discuss strategies on how to work under pressure and in times of increased stress.

TRAINEE AND EDUCATOR HUB

Room 155

Career Planning as an International Medical Graduate

4:15 p.m.–5:15 p.m.

Speakers will discuss the path to a successful career in neurology as an International Medical Graduate (IMG), with a focus on academic growth; visa issues faced by IMG neurologists; challenges and opportunities for IMG neurologists pursuing academic career; and recruitment and counseling strategies for IMG neurologists.

WELLNESS HUB

Northeast Lobby: Level 2

Bollywood Dance

3:00 p.m.–3:30 p.m.

Liven up your afternoon and get moving with a Bollywood dance lesson from Parichita Choudhury, MD.

RESEARCH HUB

North Lobby

Preparing Research Manuscripts for Publication in Neurological Journals

2:00 p.m.–2:45 p.m.

Josep O. Dalmau, MD, PhD, FAAN; Anthony A. Amato, MD, FAAN; Massimo Pandolfo, MD, FAAN; José G. Merino, MD, MPhil, FAAN; Barbara C. Jobst, MD, FAAN; and Olga Ciccarelli, PhD, FRCP, will share practical advice for writing papers for publication in neurologic journals and address issues such as the role of reporting guidelines, study registration, journal policies, and the manuscript handling process.

Optimizing Social Media Use for Academic Medicine

3:00 p.m.–3:45 p.m.

Let’s discuss the appropriate use of social networking sites and social media platforms for research, education, collaboration, and promotion.

Coffee Connect: Meet NIH Staff

Monday, 8:00 a.m.–9:00 a.m.

Coffee Connects for different audiences and topics will occur daily in the Research Hub from 8:00 a.m. to 9:00 a.m. Join us tomorrow to connect with National Institutes of Health staff about all things research.

Zecavati

Dalmau Amato Pandolfo Merino

Jobst Ciccarelli

Kamal R. Chemali, MD, and students from the New England Conservatory of Music explore the mechanisms of music perception by the brain.

What Are Your Colleagues Saying?

JOIN THE CONVERSATION! SHARE YOUR THOUGHTS AT #AANAM.

Today’s Neuroscience in the Clinic Session to Address What Should a Neurologist Know About Pregnancy and Lactation?

Third Annual Meeting in person

What are you most interested in learning about?

New outcomes in demyelinating disorders and neuromyelitis optica. For some reason we’re beginning to see a lot of patients with that now. Our patients often cannot afford the treatments, so I’m interested in seeing what other people in resource-poor countries are doing for treatment.

Md Karim, MBBS, MD, MRCPS, FACP Neurologist, University Hospital Limerick, Ireland

First-time attendee

What attracted you to the Annual Meeting this year?

I was interested initially but couldn’t come at first and then it was the pandemic. There are definitely a lot of sessions I want to attend. I’m doing two skills workshops—one on neuro-ophthalmology and neuro-otology and one on headache management, as we get lots of headache patients. I’m looking forward to the hands-on sessions.

Today between 3:30 p.m. and 5:30 p.m. join directors Riley Bove, MD, and Thomas McElrath, MD, PhD, along with expert faculty Nicole A. Smith, MD, MPH; Laura Chu, MD; and Nadine Bast, as they discuss major physiological changes that occur during pregnancy that may influence the course of neurologic disease, as well as the pregnancy outcome, and the major considerations regarding safety of medications during pregnancy, including consideration of placental transfer and gestational age at exposure. The presenters will also discuss the major considerations regarding safety of medications used for neurologic conditions during lactation.

The session will conclude with a panel discussion along with opportunity for questions. Attendees may claim two CME credits.

Nicole Pang, MD

Resident, Quezon City, Philippines

First-time

attendee

What brings you to the Annual Meeting?

I submitted an abstract, and luckily I got accepted.

What is the topic of your abstract?

Thallium scans for identifying malignant versus nonmalignant lesions.

What are you looking forward to?

Mostly I would like to get ideas for research. I’m overwhelmed with all the programs, so I’m focused on those you can’t review online—some of the hubs. I’m going to a boot camp for research today.

Bove McElrath

Ifeyinwa Ani-Osheku, MBBS Neurologist, Asokoro Abuja, Nigeria

Celebrate These 2023 AAN Service Award Recipients

The AAN recognizes the 2023 AAN service award recipients and their contributions to the art and science of neurology.

AAN PRESIDENT’S AWARD

Elaine C. Jones, MD, FAAN

Access TeleCare, Sarasota, FL

AMBASSADOR AWARD

Sponsored by the American Brain Foundation.

Peter Frampton

BOARD CHAIR AWARD

Sponsored by the American Brain Foundation.

Jane Ransom

American Brain Foundation, Minneapolis, MN

GENERAL NEUROLOGY AWARD

Sponsored by the American Academy of Neurology.

Michael Weintraub, MD, FACP, FAAN, FAHA

New York Medical College, Tarrytown, NY

KENNETH M. VISTE JR., MD

PATIENT ADVOCATE OF THE YEAR AWARD

Sponsored by the American Academy of Neurology and endowed by gifts from Dr. Viste’s colleagues, friends, and patients.

Geetanjali S. Rathore, MD, FAAN Children’s Hospital and Medical Center, Omaha, NE

MRIDHA SPIRIT OF NEUROLOGY HUMANITARIAN AWARD

Sponsored by the American Brain Foundation and funded through the philanthropy of Dr. and Mrs. Mridha.

Gretchen Birbeck, MD, MPH, DTMH, FAAN

University of Rochester, Rochester, NY

Bhim Sen Singhal, MD, FAAN

Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India

Olha Tychkivska, MD

St. Nicholas Lviv City Children’s Clinical Hospital, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

NEUROLOGY PRACTICE AWARD

Sponsored by the American Academy of Neurology.

NeurAbilities Healthcare Voorhees, NJ

PUBLIC LEADERSHIP IN NEUROLOGY AWARD

Sponsored by the American Brain Foundation. Arianna Huffington

QI INNOVATION AWARD

Sponsored by the American Academy of Neurology.

Fazila Aseem, MD, MPH

University of North Carolina School of Medicine, Chapel Hill, NC

Pravin Khemani, MD, FAAN

Swedish Neuroscience Institute, Seattle, WA

TED BURNS HUMANISM

IN NEUROLOGY AWARD

Sponsored by the American Brain Foundation. Deanna Saylor, MD, MHS Johns Hopkins University School of Medicine, Baltimore, MD

VOLUNTEER SERVICE AWARD

Sponsored by the American Academy of Neurology.

Praveen Kumar Yadav, MBBS, MD, DM, FAAN, MRCP, FRCP, FEBN, MNAMS

Aarogyam Neuroclinic, Durgapur, West Bengal, India

DISCOVER THE POWER OF PROOF

The only skin-based test to help diagnose Parkinson’s disease and other synucleinopathies

Sections Showcase Turns Spotlight on Wide Variety of Subspecialty and Other Issues of Interest

Visit room 254A of the convention center this week for the Sections Showcase which will be turning the spotlight on a wide variety of subspecialty and special interest issues throughout the week. AAN Sections—of which there are now 41—cross collaborated on topics to showcase a broad range of topics of interest. The showcase events are open to all Annual Meeting attendees. Staff will be on hand in the Sections Showcase room to share information and answer any questions about how you can join one or more AAN Sections and its corresponding Synapse SM Member Communities conversations. You can also learn more about AAN Sections and Synapse at AAN.com/Sections.

SUNDAY

3:30 p.m.–4:30 p.m.

Women’s Issues in Neurology Section Spotlight on Neurologic Disease Through the Lens of Sex and Gender

MONDAY

8:00 a.m.–9:00 a.m.

Stoke & Vascular Neurology Section Spotlight on Strategies for Pre-hospital Identification and Management of Stroke

12:00 p.m.–1:00 p.m.

Sports Neurology Section Spotlight on Updates and Changes in the Field of Sports Concussion

2:00 p.m.–3:00 p.m.

Movement Disorders and Sleep Sections Spotlight on Wellness in Neurodegenerative Disease—Proactive Lifestyle Choices

3:30 p.m.–4:30 p.m.

Neurohealth & Integrative Neurology Section Spotlight on Integrating Brain Health in Clinical Practice: An Interactive Panel Discussion

5:00 p.m.–6:00 p.m.

Clinical Neurophysiology Section Spotlight on Spectrum of Diseases and Clinical Interests in Overlapping Fields

TUESDAY

8:00 a.m.–9:00 a.m.

Child Neurology Section Spotlight on Genetic Testing in Children: What and When to Do It

12:00 p.m.–1:00 p.m.

Neuro-oncology Section Spotlight on Health Equity in Neurology

2:00 p.m.–3:00 p.m.

History Section Spotlight on AAN’s First Female CEO: A Conversation with Retired CEO Catherine M. Rydell, CAE, conducted by Christopher J. Boes, MD, FAAN

3:00 p.m.–4:00 p.m.

History Section Spotlight on Women in Neurology

5:00 p.m.–6:00 p.m.

Government Services Section

WEDNESDAY

8:00 a.m.–9:00 a.m.

Headache and Facial Pain Section

12:00 p.m.–1:00 p.m.

Endovascular & Interventional Section Spotlight on Building an Integrated Interventional Neurology Practice

Medical students active in Student Interest Groups in Neurology (SIGN) chapters across the country presented at a session on engaging early learners through SIGN led by A.B. Baker Section on Neurological Education Chair Dara V. Albert, DO, and Vice Chair Ana C. Felix, MD, FAAN.

Don’t Miss Today’s Publications and Online Learning Talks

TODAY

Transforming Health Care Delivery in Neurology

8:00 a.m.–8:45 a.m.

PRACTICE AND POLICY HUB (NORTHWEST LOBBY: LEVEL 2)

Luca Bartolini, MD, and Neha Dangayach, MD, MSCR, FNCS, DCE’21

NeuroPanels: Ask An Educator

12:30 p.m.–1:00 p.m.

PUBLICATIONS AREA (NORTH LOBBY)

José H. Posas, MD, FAAN, meets with Joseph I. Sirven, MD, FAAN, and Roy Strowd III, MD, MEd, MS, FAAN, to discuss the AAN’s new online learning webinar series, NeuroPanels. Learn how beneficial this program can be to you as a teaching tool and the uniqueness of being able to easily learn from experts on a national level.

Using NeuroBytes in the Exam Room

1:00 p.m.–1:30 p.m.

PUBLICATIONS AREA (NORTH LOBBY)

Wayne E. Anderson, DO, FAHS, FAAN, and Alexandra M. Miller, MD

Preparing Research Manuscripts for Publication in Neurological Journals

2:00 p.m.–2:45 p.m.

RESEARCH HUB (NORTH LOBBY)

José G. Merino, MD, MPhil, FAAN; Olga Ciccarelli, MD, PhD, FRCP; Anthony A. Amato, MD, FAAN; Josep O. Dalmau, MD, PhD, FAAN; Barbara C. Jobst, MD, PhD, FAAN; Massimo Pandolfo, MD, FAAN

Editors’ Highlights of the Neurology Minute® and Neurology ® Podcast

3:30 p.m.–4:00 p.m.

PUBLICATIONS AREA (NORTH LOBBY)

Stacey L. Clardy, MD, PhD, FAAN; Jeffrey B. Ratliff, MD; Jason Crowell, MD

MONDAY

Utilizing NeuroBytes in Your Clerkship – Identifying NeuroBytes that Cover Areas of Your Curriculum

11:30 p.m.–12:00 p.m.

PUBLICATIONS AREA (NORTH LOBBY)

Jeremy Moeller, MD, FAAN, and Adam Quick, MD

Meet the Editor-in-Chief of Neurology Today ® : Q&A with Dr. Joseph E. Safdieh

1:00 p.m.—1:30 p.m.

PUBLICATIONS AREA

Joseph E. Safdieh, MD, FAAN

Disputes & Debates: Pulled from the Pages of Neurology ®: Meet the Editors and Learn More

1:30 p.m.–2:00 p.m.

PUBLICATIONS AREA (NORTH LOBBY)

Steven Galetta, MD, FAAN; Aravind Ganesh, MD, DPhil (OXON), FRCPC; Ariane Lewis, MD

Neurology Quiz LIVE

2:00 p.m.–2:30 p.m.

PUBLICATIONS AREA (NORTH LOBBY)

Prasanna Venkatesan Eswaradass, MD

Meet the Editors of Neurology : All Questions Welcome

2:30 p.m.–3:00 p.m.

PUBLICATIONS AREA (NORTH LOBBY)

José G. Merino, MD, MPhil, FAAN; Luca Bartolini, MD; Josep O. Dalmau, MD, PhD, FAAN; Stefan M. Pulst, MD, FAAN; Roy E. Strowd III, MD, MEd, MS, FAAN

Neurology Today Panel Discussion and Q&A: Career Consult

4:00 p.m.–4:45 p.m.

ACADEMIC HUB (SOUTHEAST LOBBY B2: LEVEL 1)

Joseph E. Safdieh, MD, FAAN; Neil A. Busis, MD, FAAN; Temitayo Oyegbile-Chidi, MD, PhD; Andrew Spector, MD, FAASM; Barney Stern, MD, FAAN

Editorial Career Path for Educators

4:30 p.m.–5:00 p.m.

TRAINEE AND EDUCATOR HUB (NORTHEAST LOBBY B1: LEVEL 1)

Roy E. Strowd III, MD, MEd, MS, FAAN

All the Current Buzz–Meet the Editor of Practice

Current and Practice Buzz

5:00 p.m.–5:30 p.m.

PUBLICATIONS AREA (NORTH LOBBY)

Aravind Ganesh, MD, DPhil (OXON), FRCPC

Why are clinical trials so slow?

Why are clinical trials so slow?